Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226)

Affiliations

¹ Retina Consultants, Ltd, Des Plaines, Illinois; Department of Ophthalmology and Visual Science, The University of Chicago, Chicago, Illinois. Electronic address: michaelblairmd@gmail.com.
² Department of Ophthalmology and Visual Science, The University of Chicago, Chicago, Illinois.
³ Illinois Eye and Ear Infirmary, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois.
⁴ Retina Consultants, Ltd, Des Plaines, Illinois.

Comment

Michael P Blair et al. Ophthalmology. 2018 Oct.

. 2018 Oct;125(10):e70-e71.

doi: 10.1016/j.ophtha.2018.04.011.

¹ Retina Consultants, Ltd, Des Plaines, Illinois; Department of Ophthalmology and Visual Science, The University of Chicago, Chicago, Illinois. Electronic address: michaelblairmd@gmail.com.
² Department of Ophthalmology and Visual Science, The University of Chicago, Chicago, Illinois.
³ Illinois Eye and Ear Infirmary, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois.
⁴ Retina Consultants, Ltd, Des Plaines, Illinois.

No abstract available

Comment in

Reply.
Lepore D, Ji MH, Quinn G. Lepore D, et al. Ophthalmology. 2018 Oct;125(10):e71-e72. doi: 10.1016/j.ophtha.2018.04.012. Ophthalmology. 2018. PMID: 30243342 No abstract available.

Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E. Lepore D, et al. Ophthalmology. 2018 Feb;125(2):218-226. doi: 10.1016/j.ophtha.2017.08.005. Epub 2017 Sep 1. Ophthalmology. 2018. PMID: 28867130 Clinical Trial.